Versican modulates tumor-associated macrophage properties to stimulate mesothelioma growth.
Chondroitin sulfate proteoglycan core protein 2
extra-cellular matrix
monocytes/macrophages
pleural neoplasms
tumor-immunology
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
Historique:
received:
28
06
2018
revised:
25
09
2018
accepted:
04
10
2018
entrez:
5
2
2019
pubmed:
5
2
2019
medline:
5
2
2019
Statut:
epublish
Résumé
Versican promotes experimental tumor growth through cell- and non cell-autonomous mechanisms. Its role in mesothelioma progression has not been investigated so far. In this study we investigated the impact of tumor-derived versican in mesothelioma progression and the underlying mechanism of its action. For this purpose, versican-silenced or control ΑΕ17 and ΑΒ1 murine mesothelioma cells were intrapleuraly injected into syngeneic mice, in order to create pleural mesotheliomas and pleural effusions. Intratumoral and pleural immune subsets were assessed using flow cytometry. Mesothelioma cells were co-cultured with syngeneic macrophages to examine versican's impact on their interaction and endothelial cells to assess the effect of versican in endothelial permeability. Versican expression was assessed in human mesotheliomas and mesothelioma-related pleural effusions and benign pleural tissue and effusions. We observed that, versican silencing reduced mesothelioma mass and pleural fluid volume by affecting tumor cell proliferation and apoptosis
Identifiants
pubmed: 30713792
doi: 10.1080/2162402X.2018.1537427
pii: 1537427
pmc: PMC6343798
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
e1537427Références
J Biol Chem. 2001 Apr 20;276(16):13372-8
pubmed: 11278559
J Immunol. 2003 Nov 15;171(10):5051-63
pubmed: 14607902
FASEB J. 2004 Apr;18(6):754-6
pubmed: 14766798
Br J Cancer. 2005 Feb 14;92(3):587-93
pubmed: 15668716
Respirology. 2005 Jun;10(3):266-83
pubmed: 15955137
Lancet. 2005 Jul 30-Aug 5;366(9483):397-408
pubmed: 16054941
Cell. 2006 Feb 24;124(4):783-801
pubmed: 16497588
Nat Protoc. 2008;3(6):1085-91
pubmed: 18546599
J Natl Cancer Inst. 2008 Oct 15;100(20):1464-76
pubmed: 18840818
Curr Protoc Immunol. 2008 Nov;Chapter 14:Unit 14.1
pubmed: 19016445
Nature. 2009 Jan 1;457(7225):102-6
pubmed: 19122641
J Neurosci. 2009 Jun 17;29(24):7731-42
pubmed: 19535585
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Am J Pathol. 2011 Dec;179(6):3056-65
pubmed: 22001346
Oncogene. 2013 Jan 24;32(4):528-35
pubmed: 22370646
Am J Respir Crit Care Med. 2012 Sep 15;186(6):487-92
pubmed: 22652027
Mol Cancer Res. 2013 May;11(5):443-55
pubmed: 23449934
Matrix Biol. 2014 Apr;35:34-41
pubmed: 24444773
Matrix Biol. 2014 Apr;35:152-61
pubmed: 24513039
Eur Respir J. 2014 Sep;44(3):754-64
pubmed: 24525443
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953
Neuro Oncol. 2015 Feb;17(2):200-10
pubmed: 25452390
J Clin Invest. 2015 Jun;125(6):2317-34
pubmed: 25915587
Ann Oncol. 2015 Sep;26 Suppl 5:v31-9
pubmed: 26223247
Respirology. 2015 Nov;20(8):1263-71
pubmed: 26245309
Oncotarget. 2016 Apr 12;7(15):20249-59
pubmed: 26959120
Nat Rev Immunol. 2016 Apr;16(4):220-33
pubmed: 27026074
Blood. 2016 Aug 4;128(5):680-5
pubmed: 27259980
Lancet Oncol. 2017 May;18(5):623-630
pubmed: 28291584
Nat Rev Cancer. 2017 Jul 25;17(8):475-488
pubmed: 28740119
Sci Rep. 2017 Dec 8;7(1):17225
pubmed: 29222454
Methods Enzymol. 1994;245:105-26
pubmed: 7539091
Cancer Immunol Immunother. 1995 Apr;40(4):241-50
pubmed: 7750122
Histochem J. 1997 Jan;29(1):21-30
pubmed: 9088942
Dev Biol. 1998 Oct 1;202(1):56-66
pubmed: 9758703